Template:Rifampin isoniazid: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Chetan Lokhande (talk | contribs)
nocaptcha
4,484 edits
Created page with "{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0"; | style="padding: 0 5px; font-size: 100%; background:#6969..."
 
Chetan Lokhande (talk | contribs)
nocaptcha
4,484 edits
No edit summary
 
(One intermediate revision by the same user not shown)
Line 2: Line 2:
| style="padding: 0 5px; font-size: 100%; background:#696969" align=center | <span style="color:WHITE;"> '''[[Rifampin isoniazid|Rifampin isoniazid]]'''</span>
| style="padding: 0 5px; font-size: 100%; background:#696969" align=center | <span style="color:WHITE;"> '''[[Rifampin isoniazid|Rifampin isoniazid]]'''</span>
|-
|-
! style="padding: 0 5px; font-size: 85%; background:WHITE" align=left | FDA Package Insert (Rifampin isoniazid<sup>®</sup>)
! style="padding: 0 5px; font-size: 85%; background:WHITE" align=left | FDA Package Insert (RIFAMATE<sup>®</sup>)
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid description|Description]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid description|Description]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid clinical pharmacology|Clinical Pharmacology]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid clinical pharmacology|Clinical Pharmacology]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid microbiology|Microbiology]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid indications and usage|Indications and Usage]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid indications and usage|Indications and Usage]]
Line 19: Line 17:
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid overdosage|Overdosage]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid overdosage|Overdosage]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid clinical studies|Clinical Studies]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid dosage and administration|Dosage and Administration]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid dosage and administration|Dosage and Administration]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid compatibility reconstitution and stability|Compatibility, Reconstitution, and Stability]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid how supplied|How Supplied]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid how supplied|How Supplied]]

Latest revision as of 18:07, 5 January 2014

Rifampin isoniazid
FDA Package Insert (RIFAMATE®)
Description
Clinical Pharmacology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages
Retrieved from "https://www.wikidoc.org/index.php?title=Template:Rifampin_isoniazid&oldid=924651"